MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Начало・Списък с акции・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Затворен

СекторЗдравеопазване

15.26 0.59

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.44

Максимум

15.42

Ключови измерители
By Trading Economics
Приходи	227M
Продажби	139M
P/E Средно за сектора	5.766 63.808
Марж на печалбата	163.843
Служители	1,796
EBITDA	1.3M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+30.72% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.6B
Предишно отваряне	14.67
Предишно затваряне	15.26

Настроения в новините

By Acuity

50%

162 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

14.24 / 14.78 Подкрепа & съпротива

Hutchison China MediTech Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.04.2026 г., 23:26 ч. UTC

Горещи акции

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16.04.2026 г., 20:41 ч. UTC

Значими двигатели на пазара

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16.04.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record High -- Market Talk

16.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16.04.2026 г., 22:51 ч. UTC

Пазарно говорене

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16.04.2026 г., 22:08 ч. UTC

Печалби

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Health Care Roundup: Market Talk

16.04.2026 г., 20:49 ч. UTC

Печалби

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16.04.2026 г., 20:43 ч. UTC

Печалби

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16.04.2026 г., 20:40 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

16.04.2026 г., 20:40 ч. UTC

Пазарно говорене

Печалби

Netflix Says Engagement Quality Hits New High -- Market Talk

16.04.2026 г., 20:30 ч. UTC

Горещи акции

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16.04.2026 г., 20:25 ч. UTC

Печалби

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16.04.2026 г., 20:23 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16.04.2026 г., 20:19 ч. UTC

Печалби

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16.04.2026 г., 20:17 ч. UTC

Печалби

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16.04.2026 г., 20:17 ч. UTC

Печалби

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Сравнение с други в отрасъла

Ценова промяна

Hutchison China MediTech Ltd ADR Прогноза

Ценова цел

By TipRanks

30.72% нагоре

12-месечна прогноза

Среден 20 USD 30.72%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Hutchison China MediTech Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Hutchison China MediTech Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

14.24 / 14.78Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

162 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.